GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
GH Research PLC - Ordinary Shares (GHRS)
Company Research
Source: GlobeNewswire
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label extension phase in Q1 2025Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy adult subjects approved in the UK and recruitingCash, cash equivalents, other financial assets and marketable securities of $204.5 million DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2024, and provided updates on its business. Business Updates We announced today, in a separate press release, the promotion of Dr. Velichka “Villy“ Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Researc
Show less
Read more
Impact Snapshot
Event Time:
GHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GHRS alerts
High impacting GH Research PLC - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GHRS
News
- GH Research PLC (NASDAQ: GHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- GH Research PLC (NASDAQ: GHRS) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $31.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
- GH Research Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
- GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]Yahoo! Finance
GHRS
Earnings
- 11/14/24 - Beat
GHRS
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form 6-K
- GHRS's page on the SEC website